News by topic

Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Side-effects news

Show

From To
Side-effects
Liver toxicity uncommon with modern antiretroviral drugs, but higher risk for HIV/HCV coinfected

Recently approved antiretroviral drugs are generally well-tolerated and seldom cause serious liver enzyme elevations, although protease inhibitors are somewhat more likely to do so, researchers reported in the November 28, 2012, advance online edition of AIDS. People with HIV/HCV coinfection are more likely to experience liver toxicity, however.

Published
06 December 2012
From
HIVandHepatitis.com
Treatment guidelines
Abacavir: new studies challenge the evidence of reduced potency when viral load is high

An analysis of two studies of the new HIV integrase inhibitor dolutegravir presented at the Eleventh International Congress on Drug Therapy in HIV Infection in Glasgow had

Published
26 November 2012
By
Gus Cairns
Health monitoring in resource-limited settings
Paper Test Could Make Drug Treatment Safer

Researchers looking to make tuberculosis (TB) and HIV treatment safer have developed a paper-based test for drug-induced liver damage.

Published
19 November 2012
From
Asian Scientist Magazine
Prevention of mother-to-child transmission
Manchester study finds link between increased premature birth rate and HIV

A review of clinical records from Central Manchester University Hospitals has found more evidence of an increased rate of preterm delivery of babies born to HIV-positive

Published
15 November 2012
By
Gus Cairns
Side-effects
Phase out D4T in poor countries

D4T used to be prescribed at 40mg but was reduced to 30mg to reduce side-effects. But even at this reduced dose many patients cannot tolerate it. So do we really need a new study to look at a lower dose (20 mg) of D4T than the current one? Many people living with HIV around the world feel that we do not and that we should plan to phase out this drug completely as has been done in Europe and the United States.

Published
07 November 2012
From
Quackdown
Prevention of mother-to-child transmission
Adverse birth outcomes more frequent in women exposed to ART during pregnancy, largest-ever study confirms

Among HIV-infected women in Botswana, starting combination antiretroviral therapy during pregnancy was associated with an increased risk for adverse birth outcomes, including pre-term delivery, small for gestational age,

Published
30 October 2012
By
Carole Leach-Lemens
Health problems
Unravelling the complexity of HIV and fatigue

It is uncertain how common HIV-related fatigue is in the modern era. A team of researchers at the Royal Victoria Hospital in Newcastle-upon-Tyne in the UK have been studying fatigue in people with HIV infection and in HIV-negative people with Chronic Fatigue Syndrome (CFS) and comparing them to otherwise-healthy HIV-negative people.

Published
24 October 2012
From
CATIE
Pharmaceutical industry
Questions and answers on the assessment of the deficiencies in the safety reporting system at Roche Registration Ltd

The European Medicines Agency (EMA) and the national regulatory agencies in the European Union (EU) are currently assessing deficiencies in the medicines safety reporting system of Roche Registration Ltd and evaluating whether these impact on the overall benefit-risk profile for any of the medicines concerned. The assessment affects nineteen centrally authorised medicines as well as various medicines that have been nationally authorised. The medicines influde Invirase (saquinavir), Fuzeon (T-20, enfuvirtide) and Pegasys (pegylated interferon). The review follows the discovery that Roche had failed to report enough safety data and deaths amongst participants in registration trials in the US.

Published
23 October 2012
From
European Medicines Agency
Side-effects
Efavirenz and the brain: are we nearer to solving a mysterious side-effect?

One of the most potent HIV drugs, efavirenz, unfortunately also causes mysterious and sometimes chronic disruptions of mood, thought and sleep. Researchers may have found the key to

Published
22 October 2012
From
HIV treatment update
Side-effects
CNS symptoms common in people taking raltegravir

Approximately 10% of patients taking the antiretroviral drug raltegravir (Isentress) develop central nervous system (CNS) side-effects, research published in the online edition of AIDS shows. The development of CNS

Published
10 October 2012
By
Michael Carter
← Prev12345...65Next →

Filter by country